Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator. Its exact mechanism of action is not fully understood but is thought to involve direct relaxation of vascular smooth muscle, leading to vasodilation. It also has beta-adrenergic agonist activity.
## Primary Indications
* Treatment of peripheral vascular disease, such as intermittent claudication, arteriosclerosis obliterans, and Raynaud's disease.
* To improve blood flow in conditions where vasodilation is desired.
## Adult Dosing
* Oral: 10 mg to 20 mg three to four times daily.
* Higher doses may be used, but efficacy and safety at doses exceeding 20 mg per administration or 80 mg daily are not well established.
## Pediatric Dosing
* There is no established pediatric dose for isoxsuprine hydrochloride. Use is generally not recommended in pediatric patients due to lack of safety and efficacy data.
## Dose Adjustments
* Dose adjustments are not typically required based on renal or hepatic impairment, but caution is advised in patients with severe disease.
## Contraindications
* Hypersensitivity to isoxsuprine hydrochloride.
* Do not administer to patients in whom peripheral vasodilation is contraindicated (e.g., hypotension, shock).
## Adverse Effects
* Common: Flushing, nausea, vomiting, dizziness, weakness, nervousness, rash, gastrointestinal distress.
* Less Common: Hypotension, tachycardia, arrhythmias, blurred vision.
## Key Drug Interactions
* Other antihypertensive agents: May potentiate hypotensive effects.
* Drugs that prolong the QT interval: Increased risk of arrhythmias.
* Epinephrine: May antagonize the vasoconstrictive effects of epinephrine.
## Monitoring
* Blood pressure and heart rate.
* Signs and symptoms of peripheral vascular disease.
* Patient's response to therapy, including improvement in claudication or other symptoms.
## Clinical Pearls
* Isoxsuprine hydrochloride is often considered a second-line agent for peripheral vascular disease.
* Lifestyle modifications (e.g., smoking cessation, exercise) are crucial adjuncts to pharmacotherapy.
* Efficacy can be variable, and treatment trials should be of sufficient duration to assess response.
***
*This information is intended for healthcare professionals. Please consult the most current prescribing information and relevant clinical literature for complete details before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local institutional protocols.*
